Skip to content
PICO Portalanswers from OpenAlex

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity

PaperCitations, authors & open-access status

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity is a paper indexed in PICO Portal from OpenAlex.

How many citations does 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity have?

PICO Portalcitation count

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity has 6 citations in the OpenAlex counts PICO Portal stores.

When was 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity published?

PICO Portalyear

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity has 2022 year in the PICO Portal index.

What is the open-access status of 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity?

PICO Portaloa status

2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity has closed oa status in the PICO Portal index.

What is the DOI of 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity?

PICO Portaldoi

The DOI for 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity is on the source record.

What is the OpenAlex record for 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity?

PICO Portalopenalex

The OpenAlex for 2-LB: Semaglutide 2.4 mg Reduces the 10-Year T2D Risk in People with Overweight/Obesity is on the source record.

Related on PICO Portal

470M+ articles · 14-day free trial